+
+
Stay Informed

Visit Booth 307

ABBOTT STRUCTURAL
HEART WELCOMES YOU
TO PICS 2026

Get PICS 2026 Updates

Aug 30-Sep 2, 2026
      San Diego, CA

We are pleased to invite you to visit our booth at the upcoming Pediatric and Congenital lnterventional Cardiology Symposium (PICS) 2026, taking place August 30-September 2.

At our booth, you will have the opportunity to:

  • Get hands on deploying the Amplatzer Septal Occluder in a beating heart model.
  • Learn the latest clinical insights on the Piccolo™ device, the only PDA closure device specifically designed and FDA-approved for use in premature infants.

Our team of experts will be available to discuss how our innovations are helping improve outcomes for the most vulnerable patients.

Friday, August 28, 2026 

DINNER SYMPOSIUM
6:45 PM - 8:30 PM PST

Fellows & Early Career Dinner Symposium

Gain practical insights from renowned faculty through interactive discussion and hands-on learning featuring the Amplatzer™ Septal Occluder and Amplatzer Piccolo™ Occluder, while exploring real-world approaches to congenital structural heart interventions.

Marriott Ballrooms 3&4, 2nd Floor Lobby Level 
 

Featured Experts:

Dr. Joshua Murphy Rush University
Dr. Gareth Morgan University of Colorado Anschutz

Add to calendar

Sunday, August 30, 2026 

LUNCH SYMPOSIUM
1:00 PM - 2:00 PM PST

PDA Closure with the Piccolo Occluder:
When and Where to Close?

Join Abbott and a distinguished panel of experts for an engaging discussion focused on one of the most important and evolving topics in congenital heart intervention: when and where to close a patent ductus arteriosus (PDA).

This interactive symposium will explore patient selection, timing of intervention, multidisciplinary collaboration, and the ongoing debate surrounding bedside versus catheterization laboratory closure strategies.

Marriott Grand Ballroom, 2nd Floor Lobby Level
 

Featured Experts:

Dr. R. Allen Ligon, Jr. Children’s Heart of Atlanta
Dr. Shyam Sathanandam Niklaus Children’s Hospital
Dr. Amir Ashrafi Rady Children’s Health
Dr. Darren Berman Children’s Hospital Los Angeles
Dr. Matthew J. Gillespie The Children’s Hospital of Philadelphia

Add to calendar

Trusted to Close. Designed to Last.1,2

For healthcare providers treating congenital heart defects, our solutions are trusted by leading physicians for their proven reliability2,3 and enduring performance2,3. Engineered with compassion, they are designed to last – making the biggest impact on the smallest of lives.

AMPLATZER™ PICCOLO™ OCCLUDER

PICCOLO 3-YEAR FOLLOW-UP DATA

>99%2

PROCEDURAL
IMPLANT SUCCESS
in patients greater
or equal 2kg.

100%2

EFFECTIVE
PDA CLOSURE
At 3-year follow-up.
Only IDE patients  included
a 3 year echo.

>95%2

3-YEAR
SURVIVAL
No deaths were directly
attributed to the procedure
or device itself.

AMPLATZER™ SEPTAL OCCLUDER

AMPLATZER™ SEPTAL OCCLUDER DATA

0.012%3,4,5

RATE OF
EROSION
reduced with proper
sizing techniques.

>500,0001

AMPLATZER
SEPTAL OCCLUDERS
seid globally.

98.5%3,4,5

1 YEAR
CLOSURE RATE
risk with full implementation of
oversizing prevention techniques.

Don’t miss a beat—stay ahead with exclusive access to recorded symposia and the latest PICS 2026 insights.

MAT-2677408 | Item approved for U.S. use only.

References
  1. Sales Data on File at Abbott
  2. Morray, B. H., Sathanandam, S. K., Forbes, T., et al. (2023, August 16). 3-year follow-up of a prospective, Multi center Study of the Amplatzer™ Piccolo™ occluder for Transcatheter patent ductus arteriosus closure in children ~700 grams. Nature News. www.nature.com articles/s41372-023-01741-1
  3. Du, Hijazi, Kleinman, Silverman, Larntz. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults. Journal of the American College of Cardiology. 2002;39(11):1836-1844.
  4. Daniel R. Turner, MD; Carl Y. Owada, MD; Charlie J. Sang, Jr, MD; Muhammad Khan, MD; D. Scott Lim, MD. Closure of Secundum Atrial Septal Defects With the AMPLATZER Septal Occluder A Prospective, Multicenter, Post-Approval Study.
  5. SCAI presentation by Dr. Brian Boe, Amplatzer™ Septal Occluder Safety and Performance, Understanding the Data, May 2, 2024.
Important Safety Information
  • AMPLATZER PICCOLO OCCLUDER
  • Amplatzer Septal Occluder

  • Rx Only

    AMPLATZER PICCOLO™ OCCLUDER

    INDICATIONS AND USAGE

    The Amplatzer Piccolo™ Occluder is a percutaneous, transcatheter occlusion device intended for the nonsurgical closure of a patent ductus arteriosus (PDA).

    CONTRAINDICATIONS

    Weight < 700 grams at time of the procedure; Age < 3 days at time of procedure; Coarctation of the aorta; Left pulmonary artery stenosis; Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension; Intracardiac thrombus that may interfere with the implant procedure; Active infection requiring treatment at the time of implant; Patients with a PDA length smaller than 3 mm; Patients with a PDA diameter that is greater than 4 mm at the narrowest portion.

    POTENTIAL ADVERSE EVENTS

    Potential adverse events that may occur during or after a procedure using this device may include, but are not limited to: Air embolus, Allergic reaction, Anemia, Anesthesia reactions, Apnea, Arrhythmia, Bleeding, Cardiac perforation, Cardiac tamponade, Chest pain, Device embolization, Device erosion, Death, Endocarditis, Fever, Headache/migraine, Hemolysis, Hematoma, Hypertension, Hypotension, Infection, Myocardial infarction, Palpitations, Partial obstruction of aorta, Partial obstruction of pulmonary artery, Pericardial effusion, Pericarditis, Peripheral embolism, Pleural effusion, Pulmonary embolism, Re-intervention for device removal, Respiratory distress, Stroke, Thrombus, Transient ischemic attack, Valvular regurgitation, Vascular access site injury, Vascular occlusion, Vessel perforation.

  • Rx Only

    AMPLATZER™ SEPTAL OCCLUDER AND DELIVERY SYSTEM

    INDICATION FOR USE


    The Amplatzer™ Septal Occluder is a percutaneous, transcatheter, atrial septal defect closure device intended for the occlusion of atrial septal defects (ASD) in secundum position or patients who have undergone a fenestrated Fontan procedure and who now require closure of the fenestration. Patients indicated for ASD closure have echocardiographic evidence of ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload (such as, 1.5:1 degree of left-to-right shunt or RV enlargement).

    CONTRAINDICATIONS

    The Amplatzer™ Septal Occluder is contraindicated for the following: Any patient known to have extensive congenital cardiac anomaly which can only be adequately repaired by way of cardiac surgery; Any patient known to have sepsis within 1 month prior to implantation, or any systemic infection that cannot be successfully treated prior to device placement; Any patient known to have a bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy, unless another antiplatelet agent can be administered for 6 months; Any patient known to have a demonstrated intracardiac thrombi on echocardiography (especially left atrial or left atrial appendage thrombi); Any patient whose size (such as, too small for transesophageal echocardiography probe, catheter size) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization; Any patient where the margins of the defect are less than 5 mm to the coronary sinus, inferior vena cava rim, AV valves, or right upper lobe pulmonary vein.

    POTENTIAL ADVERSE EVENTS

    Potential adverse events may occur during or after a procedure placing this device may include, but are not limited to: Air embolus; Allergic dye reaction; Anesthesia reactions; Apnea; Arrhythmia; Cardiac tamponade; Death; Embolization; Fever Hypertension/hypotension; Infection including endocarditis; Need for surgery; Pericardial effusion; Perforation of vessel or myocardium; Pseudoaneurysm including blood loss requiring transfusion; Stroke; Tissue erosion; Thrombus formation on discs; Valvular regurgitation.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. VISITOR INTERNATIONAL VISITOR

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+